Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective

Overview of attention for article published in Breast cancer targets and therapy, November 2012

Altmetric Badge

Mentioned by

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 1,020 followers.

Research @DovePress shows combining herceptin w/Xeloda is the most expensive bt not best for survival r quality of life http://t.co/y9byvxjq

News @DovePress: Xeloda is costs much less than herceptin + xeloda for stage 4 #breastcancer & patients live as long http://t.co/Pipe4p2O

Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic an... http://t.co/WBzS6G5w